CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday.
Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space. Over the course of the last month, the Company has enjoyed a consistent period of bullish trading, seeing its shares soar above the 30% mark. Premier opened Monday's trading session at $0.68 per share, up 1.88% in early morning trading, undoubtedly riding out momentum gained from a month of exciting announcements regarding the Company's plans for growth.
Earlier this month, Premier Health Group (PHGRF) (PHGI) announced that, in an effort to advance its overarching strategy to cover all major verticals associated with primary care as well as develop innovative approaches that combine human skill-based expertise with emerging technologies, it had signed a binding LOI to acquire all outstanding securities of Cloud Practice Inc.
Dr. Essam Hamza, CEO of Premier Health, said: "We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system."
Akers Biosciences, Inc (AKER) enjoyed positive gains in early morning trading on Monday as its shares shot up 5.11% to $1.35 per share. Back in March, the Company, known for its development of rapid health information technologies, announced that it had entered into a three-year National Distribution Agreement with Diagnostica Stago, inc for the sale of the Company's flagship rapid test for Heparin-induced thrombocytopenia across the U.S.
According to a press release issued at the time, John J. Gormally, the Company's chief executive officer commented: "The addition of Stago to our growing and distinguished distributor network is a significant milestone in the commercialization of PIFA PLUSS PF4™. Stago is a recognized leader in the field of hemostasis and has a very large and established customer base to which to market our product. Through Stago, Akers Bio will gain access to a dedicated and specialized sales team who are focused exclusively on buyers of hemostasis-related products. Akers Bio is excited about the potential for near-term US sales growth through this new, additional and specialized channel to market."
vTv Therapeutics Inc (VTVT) announced, in early November, all associated achievements relevant to the Company in its third quarter earnings report.
In a press release regarding the announcement, the Company's chief executive officer commented:
''We continue to believe in the therapeutic potential of
Achillion Pharmaceuticals, Inc (ACHN), a clinical-stage biopharmaceutical company focused on championing drug treatments for those suffering fromcomplement mediated disorders, announced earlier results earlier this month for the Company's Phase 2 trials o its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and potency data for several other drugs.
"These compelling findings underscore the momentum for Achillion and our factor D portfolio as we advance three oral small molecule compounds through clinical development. Our oral factor D inhibitors have the potential to treat patients suffering from alternative pathway mediated diseases," said Joe Truitt, President and Chief Executive Officer at Achillion. "In C3G, we have completed patient dosing in our 14-day biomarker/dose ranging study and we are currently enrolling patients in our 6 and 12-month PoC trials. We now have 18 clinical sites open globally and plan to open additional sites in 2019."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.